Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by UBS Group from $174.00 to $193.00 in a report issued on Tuesday morning, Benzinga reports. UBS Group currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on NBIX. Needham & Company LLC reaffirmed a […]
Claret Asset Management Corp bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,565 shares of the company’s stock, valued at approximately $206,000. Other hedge funds and other […]
Roche vet James Sabry departs—Chutes & Ladders fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
FDA delays decision on Dupixent in COPD; Summit makes a bold claim biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective hoisted by equities research analysts at UBS Group from $174.00 to $193.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 43.37% from the company’s […]